Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Proliferative Diabetic Retinopathy, Diab...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Proliferative diabetic retinopathy (PDR) is the leading cause for blindness in working-age adults. The current gold standard treatment for PDR is panretinal photocoagulation (PRP). In current clinical practice, both single-session and multiple-session PRP approaches are widely accepted and utilized. The purpose of this study is to compare the safety and effectiveness of single-session and multiple-session PRP.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Single-session panretinal PRP (SS-PRP) — Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.
  • Procedure: Multiple-session panretinal PRP (MS-PRP) — Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.

Primary Outcomes

  • Central subfield retinal thickness (CRT) (Baseline and 1, 3 and 6 months after treatment)
  • Vessel Perfusion Density (VPD) (Baseline and 1, 3 and 6 months after treatment)
  • Vessel Length Density (VLD) (Baseline and 1, 3 and 6 months after treatment)
  • Foveal Avascular Zone (FAZ) (Baseline and 1, 3 and 6 months after treatment)
  • Lesion size (Baseline and 1, 3 and 6 months after treatment)
  • Macular volume (Baseline and 1, 3 and 6 months after treatment)
  • Venular saturation (Baseline and 1, 3 and 6 months after treatment)
  • Arteriolar saturation (Baseline and 1, 3 and 6 months after treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-01
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Principal Investigators:
  • Marita Andersson Grönlund, M.D. Prof (PRINCIPAL_INVESTIGATOR) - Göteborg University
Contact Information
Study Contact:
Imadeddin Abu Ishkheidem, M.D.
+46738744867
imadeddin.abu.ishkheidem@vgregion.se
Sofia Töyrä Silfverswärd, PhD
+46761283085
sofia.toyra.silfversward@vgregion.se
Imadeddin Abu Ishkheidem, M.D.
+46738744867
imadeddin.abu.ishkheidem@vgregion.se
Ögonmottagning Mölndal/SU
Interventions
  • Procedure: Single-session panretinal PRP (SS-PRP) — Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas in one comprehensive session, typically delivered in a single clinical visit.
  • Procedure: Multiple-session panretinal PRP (MS-PRP) — Administration of panretinal photocoagulation (PRP) treatment with navigated laser using Navilas over two separate visits with at least one week apart.
Study Locations (1 sites)
Ögonmottagning Mölndal/SU, Mölndal, 43130 Sweden
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years. * Patients with type 1 or type 2 Diabetes Mellitus with newly diagnosed Proliferative Diabetic Retinopathy, PDR. * Visual acuity ≥ 0.1 Snellen. * CRT of less than 300 micrometer measured by OCT without cysts in the neuroretina. * Clear media and adequately dilated pupil for PRP. Exclusion Criteria: * Intraocular surgery within the last 4 months or planned within the next 3 months. * Previous or current center-involved diabetic macular edema (Ci-DME). * Previous PRP, intravitreal treatment (IVT), or macular laser treatment in study eye. * Treatment with medications known to risk macular edema. * Media opacity preventing adequate PRP. * General medical condition making office laser treatment very difficult or impossible.
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 20
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to integrate various data types, such as electronic health records, wearable device data, and environmental data, to create a comprehensive, personalized diabetes care model. The study will focus on people with type 2 diabetes living in specified vulnerable zip codes.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Observational Study: Relationships Among Glucose, Physical Activity and Environmental Influences — This is a single group observational study with no interventions.

Primary Outcomes

  • The primary outcome is to collect and analyze continuous interstitial glucose measurements in 20 individuals with type 2 diabetes over a period of 20 days using a DEXCOM G7 continuous glucose monitor (CGM). (20 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-25
Completion: 2026-01-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Principal Investigators:
  • Andy Boyd, MD (PRINCIPAL_INVESTIGATOR) - University of Illinois at Chicago
Contact Information
Study Contact:
Laurie Quinn, PhD
312 771 6497
lquinn1@uic.edu
Sulaimon Balogun, PhD Student
773-971-0503
sbalog6@uic.edu
Laurie Quinn, PhD RN
312-996-7906
lquinn1@uic.edu
University of Illinois - Chicago
Interventions
  • Other: Observational Study: Relationships Among Glucose, Physical Activity and Environmental Influences — This is a single group observational study with no interventions.
Study Locations (2 sites)
University of Illinois - Chicago, Chicago, Illinois 60612 United States
University of Illinois College of Nursing, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria * People with diabetes in the 18-65 years of age range * Diagnosed with type 2 diabetes * Resides in the specified high social vulnerability zip codes - 60619, 60620, 60621, 60636, 60644, 60624, 60609, 60612, 60617, 60623, 60628, 60629, 60639, 60645, 60649, 60651, 60652, 60653 * Speak and understand the English language * Willing to wear various devices (CGM and sports wristband) * Own a smartphone Exclusion Criteria * Subjects will be excluded from the study for the following reasons: * Any concern of not understanding informed consent * Unable to understand or unwilling to follow research protocol
Conditions Insulin Resistance, Polycystic Ovary Syn...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The study aims to investigate the relationship between fasting insulin and Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) across various demographic factors, including age, sex, race/ethnicity, BMI, and polycystic ovary syndrome (PCOS) diagnosis. By analyzing these variables, the study seeks to identify potential variations in insulin levels, which could provide valuable insights into the impact of different factors on metabolic health and the development of insulin-related conditions.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Primary Outcomes

  • Assessment of Fasting Insulin levels and HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) scores among different groups stratified by age, sex, race/ethnicity, BMI, and PCOS (Polycystic Ovary Syndrome) diagnosis. (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-02-01
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ali Chappell
Principal Investigators:
  • Ali M Chappell (PRINCIPAL_INVESTIGATOR) - Insara
Contact Information
Study Contact:
Ali M Chappell, PhD, MS, RD
4092070443
research@insara.com
Ali M Chappell, PhD, MS, RD
8064417275
achappell@lillihealth.com
Lilli Health
Interventions
N/A
Study Locations (1 sites)
Lilli Health, Houston, Texas 77554 United States
Eligibility Criteria
Inclusion Criteria Age: Participants aged 18+ years Sex: Both males and females Race/Ethnicity: Participants from diverse racial and ethnic backgrounds BMI: Participants across a range of body mass index (BMI) values PCOS Diagnosis: Participants with and without a confirmed diagnosis of PCOS based on established diagnostic criteria Participants must have completed metabolic testing within one month prior to enrollment, including: * Fasting insulin * Hemoglobin A1c (A1c) * Complete lipid panel * Triglycerides Laboratory testing must be completed through a healthcare provider, an independent laboratory, or by using an Insara Insulin Testing Kit Laboratory values must be obtained following a minimum 8-hour fast Participants must have complete laboratory data for all required measures Exclusion Criteria Age: Participants below 18 years Sex: None. Both males and females are included Race/Ethnicity: None. Participants from all racial and ethnic backgrounds are included Endocrine Disorders: Participants with other endocrine disorders affecting insulin levels (e.g., insulin-secreting tumors) Significant recent weight change: Loss of more than 5% of body weight within the previous month Pregnancy or breastfeeding Acute illness or infection within the past 2 weeks Use of medications known to significantly affect insulin or glucose metabolism will be recorded and accounted for in analysis
Conditions Chronic Kidney Disease
Phase PHASE1
Enrollment 124
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD).

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: AZD4248 — AZD4248 will be administered orally.
  • Drug: Placebo — Placebo will be administered orally.
  • Drug: AZD4248 — AZD4248 will be administered via IV infusion.
  • Drug: Placebo — Placebo will be administered via IV infusion.

Primary Outcomes

  • Parts A, B, and C: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) (From Day 1 to Follow Up visit (Part A: up to 12 days; Part B and C: up to 19 days))
  • Part D: Intra- and inter-participant variability of estimated glomerular filtration rate (eGFR) derived from home self-testing device measurements (Day 1 to Day 169)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-06-09
Completion: 2026-12-25
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Collaborators: Parexel
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: AZD4248 — AZD4248 will be administered orally.
  • Drug: Placebo — Placebo will be administered orally.
  • Drug: AZD4248 — AZD4248 will be administered via IV infusion.
  • Drug: Placebo — Placebo will be administered via IV infusion.
Study Locations (5 sites)
Research Site, Glendale, California 91206 United States
Research Site, Chicago, Illinois 60643 United States
Research Site, Ann Arbor, Michigan 48109 United States
Research Site, Saint Paul, Minnesota 55114 United States
Research Site, San Antonio, Texas 78215 United States
Eligibility Criteria
Key Inclusion Criteria: \- Healthy participants with suitable veins for cannulation or repeated venipuncture. Parts A and B: * Have a body mass index (BMI) between 18 and 30 kilograms per millimeter (kg/m2), inclusive. * For Chinese participants (Part A2): participants are to be Chinese, defined as having both parents and 4 grandparents who are Chinese. This includes second and third generation participants of Chinese descent whose parents or grandparents are living in a country other than China. * For Japanese participants (Part B2): participants are to be Japanese, defined as having both parents and 4 grandparents who are Japanese. This includes second and third generation participants of Japanese descent whose parents or grandparents are living in a country other than Japan. Part C: * Have a BMI between 20 and 40 kg/m2, inclusive. * Have a diagnosis of diabetic kidney disease (DKD). * Hemoglobin A1C (HbA1c) of ≤ 10.5%. * Participants are required to be on a stable dose of angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for at least 6 weeks prior to Visit 1 and throughout the Screening Period. In addition, participants should be on stable doses of all other medication for ≥ 6 weeks before Screening. Part D: * Have a BMI between 20 and 35 kg/m2, inclusive. * Have a diagnosis of DKD as defined by a) diagnosis of type 2 diabetes (T2D) b) eGFR values and c) urine albumin to creatinine ratio (UACR) values. * HbA1c of ≤ 10.5%. * Participants are required to be on a stable dose of ACEi or ARB for at least 6 weeks prior to Visit 1 and throughout the Screening Period. In addition, participants should be on stable doses of all other medication for ≥ 6 weeks before Screening. * Participants must be able and motivated to use the home creatinine device and smartphone independently by successfully performing the test without assistance from site staff. * Participants must be able to read and understand English sufficient to participate in site visits and home testing. Key Exclusion Criteria: * History of any clinically important disease or disorder which may put the participant at risk because of participation in the study or influence the results. * Any positive result on Screening for serum hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or human immunodeficiency virus (HIV). Parts A and B: * History or presence of gastrointestinal, hepatic, or renal disease. * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4248. * Participants who have previously received AZD4248. Part C: * History or presence of gastrointestinal, hepatic, or renal disease. * Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to AZD4248. * Use of drugs that are strong or moderate CYP3A4 inhibitors/inducers or P-gp inhibitors from within 3 weeks before Screening until the end of the last sample collection. * Participants who have previously received AZD4248. * Participants on serum creatinine-altering drugs should be on long-term treatment at a stable dose prior to study entry. * Expected change of dosing regimen during the study. * History of clinically significant heart or vascular disease. * New York Heart Association Class 2, 3, or 4 or history of hospitalization for heart failure within 6 months of screening. * Ventricular arrhythmias requiring treatment. * Amputation due to peripheral artery disease. * Severe chronic obstructive pulmonary disease as judged by the Investigator or hospitalization for exacerbation in the last 6 months. Part D: * Participants on serum creatinine-altering drugs should be on long-term treatment at a stable dose prior to study entry. * Expected change of dosing regimen during the study.

Microbiome and Atopy in Mali

NCT07051902
Recruiting
Conditions Atopic Disease
Phase Not Applicable
Enrollment 288
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study is about allergic diseases in people living in Mali. Allergic diseases can cause health problems like asthma or skin rashes. In this study, the investigators will look for clues about things that may affect whether people get allergic diseases. The investigators will look at things on or in the body, like germs, and things in the environment, like pollution. To do this, the investigators will collect different types of biological samples, health information, and environmental information from people with allergic diseases and people without allergic diseases. The investigators will compare what is found in each group to look for differences that might be related to allergic disease.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • Differences in gut microbiome between atopic patients and healthy controls in children and adults. (Within 28 days after the screening visit.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-30
Completion: 2026-12
Eligibility
Age: 3 Years and older
Sex: ALL
Volunteers: true
Enrollment: 288 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigators:
  • Ian Myles, MD (PRINCIPAL_INVESTIGATOR) - NIAID, National Institutes of Health (NIH)
  • Kingsley Osei-Karikari (STUDY_CHAIR) - National Institutes of Health (NIH)
Contact Information
Study Contact:
Cisse Lamissa, MD
+223 66956944
lamissa05@gmail.com
Khadida Ouattara, MD, MSc
+223 66780357
zankhadi@gmail.com
Cisse Lamissa, MD
+223 66956944
lamissa05@gmail.com
Dermatology Hospital of Bamako
Interventions
N/A
Study Locations (2 sites)
Dermatology Hospital of Bamako, Bamako, Mali
Pneumology Ward, Point G University Hospital, Bamako, Mali
Eligibility Criteria
Inclusion Criteria (Study Group): * Aged ≥3 years. * Able to provide informed consent (for ages ≥18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \<18 years). * Positive Screening questionnaire for asthma or eczema. * Diagnosed with atopic dermatitis or asthma via physician diagnosis and criteria as follows: * Clinical diagnosis of atopic disease, as defined by Hanifin and Rajka criteria, that has been present for ≥3 months before the screening visit. Inclusion Criteria (Healthy Volunteers): * Aged ≥3 years. * Able to provide informed consent (for ages ≥18 years) or has a parent or guardian who can provide informed consent on their behalf (for ages \<18 years). * Negative Screening questionnaire for asthma and eczema. * In good general health as evidenced by medical history and not diagnosed with atopic dermatitis or asthma via physician diagnosis. * Failure to meet Hanifin and Rajka criteria and \<3 on GINA guidelines for asthma diagnosis. * No self-reported history of food allergy. Exclusion Criteria: * Use of antibiotics in the 3 months prior to screening. * Current pregnancy or lactation (determined by self-report). * Treatment with an investigational drug within 12 months prior to screening. * Current smoker or tobacco use within 4 months prior to screening. * Current skin infections other than atopic dermatitis (e.g., scabies). * Active diarrhea as defined by three or more loose stools per day (Bristol stool scale score of 6 or 7). * Presence of current bacterial, viral, or fungal infection, with the exception of isolated onchomycosis, which is not exclusionary. * Any other condition or factor that the investigator determines may significantly influence the results of testing.
Conditions Chronic Cough (CC), Asthma
Phase PHASE1
Enrollment 33
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The inhalation of adenosine 5'-triphosphate (ATP) to evoke cough (ATP cough challenge) is becoming increasingly used as a tool to measure cough hypersensitivity in patients with chronic cough. However, the safety, feasibility, and repeatability of this procedure is not widely known. In this study, we will perform ATP cough challenges in healthy individuals and in patients with mild asthma and chronic cough to better understand the safety, feasibility, and repeatability of these challenges. Such information will guide the future conduct of ATP cough challenges to measure cough hypersensitivity and identify patients who may better respond to ATP-blocking therapies.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Drug: Adenosine 5'-triphosphate — Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.

Primary Outcomes

  • The mean %FEV1 change from baseline at incremental doses of ATP (Until the end of the ATP cough challenge)
  • Symptoms of wheeze measured on the mBorg scale at incremental doses of ATP (Until the end of the ATP cough challenge)
  • Symptoms of chest tightness measured on the mBorg scale at incremental doses of ATP (Until the end of the ATP cough challenge)
  • Symptoms of shortness of breath measured on the mBorg scale at incremental doses of ATP (Until the end of the ATP cough challenge)
  • The mean change in oxygen saturations (SpO2) from baseline at incremental doses of ATP (Until the end of the ATP cough challenge)
  • The intra-class correlation of measures obtained from repeat ATP cough challenges (Baseline to 1 week)
  • The frequency of adverse events (Baseline to 1 week)
  • Total maximum number of evoked coughs (Emax) by any dose of ATP (Until the end of the ATP cough challenge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-08-05
Completion: 2026-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 33 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McMaster University
Contact Information
Study Contact:
Imran Satia, MD PhD
905-525-2100
satiai@mcmaster.ca
Imran Satia, MD PhD
905-521-2100
satiai@mcmaster.ca
Respiratory Research Lab
Interventions
  • Drug: Adenosine 5'-triphosphate — Participants will inhale increasing doubling concentrations of adenosine 5'-triphosphate dissolved in 0.9% saline through the Aerogen Solo vibrating mesh nebulizer.
Study Locations (1 sites)
Respiratory Research Lab, Hamilton, Ontario L8N 3Z5 Canada
Eligibility Criteria
Phase 1: Healthy individuals Inclusion Criteria: Eligible participants in Phase 1 will include healthy adults (≥18 years old) with: 1. Normal spirometry; and 2. No current or past medical history of chronic cough or other respiratory diseases. Exclusion Criteria: We will exclude healthy individuals meeting the following: (1) Are a current or former smoker with a \>5 pack-year history and abstinence ≤6 months; 1. Unable to perform acceptable and reproducible spirometry; 2. Have unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit; 3. Have had a lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit; 4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease; or 5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study. 6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months; 7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s); 8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy; 9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant; 10. Pregnant or breastfeeding; 11. Women of child-bearing potential who: 1. Do not agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of 3 months. Acceptable methods of birth control include oral contraceptives, hormone birth control patch, vaginal contraceptive ring, injectable contraceptives, or hormone implant, double-barrier method, intrauterine devices, non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s), vasectomy of partner at least 6 months prior to screening. Females who are not of child-bearing potential will be defined as females who have undergone a sterilization procedure (e.g., hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening. Phase 2: Patients with RCC/UCC and mild-steroid naïve asthma Inclusion Criteria: Eligible participants will include adults (≥18 years old) with: 1. RCC/UCC for \>1 year, demonstrated by a normal chest radiograph and no airflow obstruction (FEV1/FVC\>0.7/LLN) with either: 1. Insufficient improvement in cough despite treatment targeting any underlying condition(s) contributing to the cough (RCC); or 2. Cough for which an underlying cause has not been determined despite thorough investigation (UCC). 2. Mild steroid-naïve asthma who demonstrate evidence of a positive screening methacholine (PC20\<16 mg/mL); symptoms of cough, shortness of breath, chest tightness, and wheeze, that, in the opinion of the qualified investigator, are well-controlled; and those have not used inhaled or oral corticosteroids for the past month. Exclusion Criteria: Cohort-specific exclusion criteria include the following: For the RCC/UCC cohort: (1) Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months; For the mild steroid-naïve asthma cohort: 1. Current smoker or ex-smoker with ≥20 pack-year history and abstinence ≤6 months; 2. History or exacerbation or uncontrolled symptoms within the last month prior to the first study visit; and 3. Use of inhaled or oral corticosteroids within the last month prior to the first study visit. We will exclude participants meeting any of the following criteria from the study: 1. Unable to perform acceptable and reproducible spirometry; 2. Unresolved symptoms of upper respiratory tract infection within 6 weeks prior to the first study visit; 3. Lower respiratory tract infection or pneumonia within 6 weeks prior to the first study visit; 4. Presence of other primary pulmonary disorders, including pulmonary embolism, pulmonary hypertension, lung cancer, cystic fibrosis, radiologically-proven emphysema, severe bronchiectasis, or severe interstitial lung disease; 5. History of psychiatric illness, drug, or alcohol abuse that could interfere with participation in the study; 6. History of clinically-significant cardiovascular disease, including coronary artery disease, aortic aneurysm, or stroke in the last 3 months; 7. Those with serious medical conditions or those who are not on stable medication(s) for their condition(s); 8. Those with immune system disorders, severe allergy, or on allergy-specific immunotherapy; 9. Any other condition, that, in the opinion of the qualified investigator, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant; 10. Pregnant or breastfeeding; 11. Female participants of child-bearing potential who: 1. Do not agree to use a medically approved method of birth control for the duration of the study; 2. Have not been using hormonal birth control for a minimum of 3 months prior to screening.
Conditions Obstructive Pulmonary Disease, Mechanica...
Phase NA
Enrollment 10
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this physiological pilot study with a randomized crossover design is to study the effect of Flow-controlled ventilation (FCV) on the minute volume compared to Volume-controlled ventilation (VCV) in intubated patients with an exacerbation of their asthma or COPD. Our hypothesis is that FCV will results in a lower minute volume compared to VCV in this patient category. Patients will be randomized between two ventilation sequences, namely 90 minutes of FCV followed by 90 minutes of VCV or vice versa.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: FCV — 90 minutes of FCV

Primary Outcomes

  • MV (90 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-17
Completion: 2027-10
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Erasmus Medical Center
Collaborators: Maasstad Hospital
Principal Investigators:
  • Diederik P Gommers, Prof. Dr. (STUDY_DIRECTOR) - Erasmus Medical Center
Contact Information
Study Contact:
Julien P Van Oosten, MD
+31630600232
j.vanoosten@erasmusmc.nl
Annemijn H Jonkman, Dr.
+31627858466
a.jonkman@erasmusmc.nl
Gommers, Professor
0031107035142
d.gommers@erasmusmc.nl
Erasmus Medical Center
Interventions
  • Device: FCV — 90 minutes of FCV
Study Locations (2 sites)
Erasmus Medical Center, Rotterdam, South Holland 3015 GD Netherlands
Maasstad Hospital, Rotterdam, South Holland 3079DZ Netherlands
Eligibility Criteria
Inclusion Criteria: * 18 years or older; * Provided written informed consent; * Undergoing controlled mechanical ventilation via an endotracheal tube; * Reason for intubation being exacerbation of asthma or COPD; * Intubated ≤72 hours Exclusion Criteria: * Severe sputum stasis or production requiring frequent bronchial suctioning (more than 5 times per nurse shift) * Untreated pneumothorax (i.e. no pleural drainage) * Hemodynamic instability defined as a mean arterial pressure below 60mmHg not responding to fluids and/or vasopressors or a noradrenalin dose \>0.5mcrg/kg/min * High (\>15 mmHg) or instable (an increase in sedation or osmotherapy is required) intracranial pressure * An inner tube diameter of 6mm or less * Anticipating withdrawal of life support and/or shift to palliation as the goal of care * Inability to perform adequate electrical impedance tomography (EIT) measurements with, e.g.: * Have a thorax circumference inappropriate for EIT-belt * Thoracic wounds, bandages or deformities preventing adequate fit of EIT-belt * Recent (\<7 days) pulmonary surgery including pneumonectomy, lobectomy or lung transplantation * ICD device present (potential interference with proper functioning of the EIT device and ICD device) * Excessive subcutaneous emphysema * Contra-indications for nasogastric tube or inability to perform adequate transpulmonary pressure measurements with, e.g.: * Recent esophageal surgery * Prior esophagectomy * Known presence of esophageal varices * Severe bleeding disorders
Conditions Mild to Moderate Asthma
Phase PHASE1
Enrollment 12
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: CDX-622 — Administered Intravenously

Primary Outcomes

  • To evaluate the safety and tolerability profile of CDX-622 in adults with mild to moderate asthma. (Day 1 up to Day 85 (12 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-01
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Celldex Therapeutics
Contact Information
Study Contact:
Celldex Therapeutics
844-723-9363
clinicaltrials@celldex.com
Mariana Mosqueda
Mariana.Mosqueda@ucsf.edu
University of California, San Francisco
Christine Nguyen
Christine.Nguyen@ucsf.edu
University of California, San Francisco
Interventions
  • Drug: CDX-622 — Administered Intravenously
Study Locations (4 sites)
University of California, San Francisco, San Francisco, California 94143 United States
The University of Kansas Medical Center, Kansas City, Kansas 66160 United States
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
University of Pittsburgh Asthma and Environmental Lung Health Institute at UPMC, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Key Inclusion Criteria: 1. Males and females, ≥ 18 years of age 2. Diagnosis of mild to moderate asthma for at least 12 months 3. Pre-bronchodilator forced expiratory volume in 1 second (FEV1) ≥ 70% of predicted normal 4. Airway reversibility ≥ 12% and 200 mL improvement in FEV1 5. Both males and females of child-bearing potential must agree to use contraception during the study and for 150 days after treatment 6. Willing and able to comply with all study requirements and procedures Key Exclusion Criteria: 1. Females who are pregnant or nursing 2. Pulmonary disease other than asthma 3. Systemic diseases with elevated eosinophils other than asthma 4. Hospitalization for treatment of asthma in the past 12 months or required oral corticosteroids due to asthma within the past 6 months 5. History of needing ventilator support due to asthma 6. Current nasal polyps 7. Severe or uncontrolled asthma 8. History of smoking or vaping within the past 6 months 9. Tuberculosis, hepatitis B or C virus, or HIV 10. Immunomodulating biologic therapies within the past 3 months for non-extended half-life biologics. 11. Prior receipt of TSLP or KIT inhibitors such as tezepelumab or briquilimab Additional protocol defined inclusion and exclusion criteria could apply.
Conditions Depression - Major Depressive Disorder, ...
Phase PHASE4
Enrollment 27
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments. This study will investigate two alternative treatment options for people whose depression has not responded to standard treatments: repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, and ketamine, a fast-acting medication. It can be difficult to decide between these interventions in clinical practice, and selecting between them often comes down to patient preference and trial and error. This study is working to optimize the selection approach: using biological and behavioral markers to match each person to identify biomarkers that may predict response to rTMS or ketamine. Investigators believe that differences in how individuals respond to rTMS versus ketamine are partly explained by differences in how their brains are organized, and that these differences can be measured and used to guide intervention decisions. This is an early-stage pilot study designed to test whether this biomarker-based approach is practical and acceptable to patients. Investigators will evaluate how well a combination of brain imaging and clinical data can predict, at the individual level, who is likely to respond to rTMS versus ketamine. The ultimate goal is to develop a reliable, scalable tool that helps clinicians make faster and more informed intervention decisions, reducing the time people with treatment-resistant depression spend searching for an antidepressant that works.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: TMS — rTMS will be administered as intermittent theta burst simulation (iTBS) delivered to the left dorsolateral prefrontal cortex with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly rTMS sessions).
  • Drug: Ketamine — Ketamine is a dissociative anesthetic with rapid-acting antidepressant properties. It will be administered in 6 total sessions (3 days x 2 weeks), each comprising a single subanesthetic dose of ketamine (0.5 mg/kg) delivered intravenously over 40 minutes.

Primary Outcomes

  • Change from Baseline to 2-Week Post-Intervention Score in Hamilton Depression Rating Scale (HDRS) Score (Baseline to 2-weeks post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-08-10
Completion: 2028-12
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 27 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Weill Medical College of Cornell University
Collaborators: Icahn School of Medicine at Mount Sinai, National Institute of Mental Health (NIMH)
Principal Investigators:
  • Conor Liston, MD, PhD (PRINCIPAL_INVESTIGATOR) - Weill Medical College of Cornell University
Contact Information
Study Contact:
Research Coordinator, Interventional Psychiatry Program
646-962-2900
tmsinfo@med.cornell.edu
Research Coordinator, Interventional Psychiatry Program
646-962-2900
tmsinfo@med.cornell.edu
Weill Cornell Medicine
Conor Liston, MD, PhD
Weill Cornell Medicine
Interventions
  • Device: TMS — rTMS will be administered as intermittent theta burst simulation (iTBS) delivered to the left dorsolateral prefrontal cortex with an accelerated intervention protocol (up to 5 consecutive days of 10 hourly rTMS sessions).
  • Drug: Ketamine — Ketamine is a dissociative anesthetic with rapid-acting antidepressant properties. It will be administered in 6 total sessions (3 days x 2 weeks), each comprising a single subanesthetic dose of ketamine (0.5 mg/kg) delivered intravenously over 40 minutes.
Study Locations (1 sites)
Weill Cornell Medicine, New York, New York 10065 United States
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Adults of all genders aged 18-70 at the time of screening 3. Diagnosis of Major Depressive Disorder (by DSM-5 criteria) 4. Depressive symptoms of at least moderate severity (GRID HDRS-17 score \>= 14 or as determined by a study clinician) 5. Failed at least 1 prior trial of standard first-line treatment for MDD per the modified Antidepressant Treatment History form, the Maudsley Staging Method, and APA Practice Guidelines (e.g., SSRI, SNRI, CBT) OR initiated and discontinued a trial of a first-line treatment for MDD (e.g. could not tolerate side effects, etc.) 6. Not currently taking antidepressants OR on a stable dose of antidepressant for at least 1month prior to screening and plans to remain off antidepressants OR on this stable dose for the duration of participation 7. Current medication regimen is compatible with safe participation in the trial in the assessment of a study clinician 8. Access to psychiatric care before, during, and after completion of the study 9. For females of reproductive potential: agreement to use effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation 10. Proficiency in English sufficient to complete assessments and follow study procedure instructions 11. Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: 1. Imminent risk of suicide 2. Presence of primary psychiatric diagnosis other than MDD (e.g., post-traumatic stress disorder, obsessive-compulsive disorder, MDD with psychotic features, primary psychotic illness, bipolar I or II disorder) 3. History of epilepsy or a history of seizures that would influence the participant's risk for TMS-evoked seizures; history of any condition / concurrent medication that could notably lower seizure threshold in the estimation of a study clinician 4. Met criteria for any clinically significant substance use disorder (by DSM-V criteria) with active substance misuse in the 6 months prior to screening 5. Lifetime history of PCP/ketamine abuse 6. History or presence of significant neurological disorder that may be contributing to current depressive symptoms in the judgment of a study clinician (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy) 7. Presence of medical contraindications to ketamine, including liver function tests \> 2.5x normal limit, recent myocardial infarction, congestive heart failure \> stage 2, angina pectoris, clinically significant bradycardia or tachycardia at the baseline assessment, or uncontrolled hypertension 8. MRI contraindication, including presence of ferromagnetic foreign metal bodies or implants, implanted or conductive ferromagnetic objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), and ferromagnetic permanent make-up that may undergo heating in an MRI scanner 9. Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation 10. Abnormal bloodwork that may be contributing to depressive symptoms in the estimation of a study clinician (e.g. indicators of clinically significant hypothyroidism, kidney failure, liver failure, etc.) 11. History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures
Conditions Treatment Resistant Depression
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Background: 30-50% of patients with Major Depressive Disorder (MDD) do not respond adequately despite two or more antidepressant treatments with proper dosage and timing of administration, configuring a condition of Treatment-Resistant Depression (TRD). Repetitive Transcranial Magnetic Stimulation (rTMS) is a neuromodulation technique that uses a magnetic field to stimulate focal cortical brain regions and it has been approved by the FDA for the treatment of TRD. Accelerated rTMS (arTMS) protocols involve multiple daily sessions of rTMS and they have been shown to be equally effective and safe compared to rTMS protocols, with reduced administration time and potentially faster antidepressant efficacy. Objectives: The main aim of this study is to identify MDD endophenotypes/biotypes predictive of response to accelerated treatment of rTMS to better characterize the clinical correlates of response in patients with TRD. Eligibility: Subjects between 18 and 65 years suffering from TRD in stable psychopharmacological treatment for at least one month. Design: This clinical trial includes three phases: 1) a screening phase; a rTMS continued treatment phase; and a follow-up. In order to be enrolled, participants will be screened with: * Medical history to assess the existence of the inclusion criteria and exclude any medical conditions that could contraindicate treatment with arTMS * Questionnaires After being enrolled, baseline data will be collected. In particular, participants will be administered: * Questionnaires * Functional MRI * Cognitive tasks * Eye examination with Electroretinography (ERG) * Blood sampling * Salivary cortisol sampling Repetitive TMS will be delivered during 5 outpatient treatment days (4 times/die). After treatment patients will be contacted by telephone on a weekly basis for the first 3 weeks, to carry out an assessment of the clinical condition. A follow-up visit, in the clinic, will be carried out after 21 days from the last stimulation (Friday), with the administration of psychometric scales. Blood samples will be taken on the first day of stimulation and the day after the last stimulation. Salivary cortisol sampling will be taken before the start of the stimulation protocol, after the first stimulation day and immediately after the last stimulation session foreseen by the protocol. fMRI will be performed during baseline and at the end of treatment. ERG will be performed before the start of the stimulation protocol, after the first stimulation and immediately after the last stimulation session foreseen by the protocol. Patients will undergo ERG again during the follow-up visit at 21 days. Treatment includes: * rTMS: A brief electrical current passes through the coil placed on the head. At each day, participants will receive four rTMS sessions (36 min), with a 55 min interval between sessions. * MRIs: Patients will undergo two MRI sessions lasting 45 min. Blood pressure and respiratory rate will be recorded…

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Accelerated Repetitive Transcranial Magnetic Stimulation — rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).

Primary Outcomes

  • Changes in psychometric test indicator of depression - MADRS (Baseline; each 1 day of treatment ; at 1, 2, 3 and 4 weeks.)
  • Changes in psychometric test indicator of depression - HAM-D 21 (Baseline; 1 week; 4 weeks)
  • Changes in neuroplasticity - structural RM and fMRI (physiological parameter) (Baseline; day 6)
  • Changes in neuroplasticity - DTI (physiological parameter) (Baseline; day 6)
  • Changes in responsivity of nervous tissue (physiological parameter) (Baseline; 4 weeks)
  • Rate of genetic polymorphism predictor of treatment response (Baseline; day 6)
  • Change in BDNF level (physiological parameter) (Baseline; day 6)
  • Change in pro-BDNF (physiological parameter) (Baseline; day 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-28
Completion: 2028-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ITAB - Institute for Advanced Biomedical Technologies
Contact Information
Study Contact:
Mauro Pettorruso, MD, PhD
+393391979487
mauro.pettorruso@unich.it
Mauro Pettorruso, MD, PhD
+393391979487
mauro.pettorruso@unich.it
ITAB
Interventions
  • Device: Accelerated Repetitive Transcranial Magnetic Stimulation — rTMS is a non-invasive brain stimulation technique. It will be used a MagPro R30 with the Cool-B-70 figure-of-eight coil (MagVenture, Falun, Denmark).
Study Locations (1 sites)
ITAB, Chieti, 66100 Italy
Eligibility Criteria
Inclusion Criteria: * Current diagnosis of Major Depressive Disorder (MDD), based on the Diagnostic and Statistical Manual of Mental Disorder - Fifth Edition (DSM-5); * Subjects without clinical response to at least two antidepressant treatments administered at adequate dosage and duration during the current episode; * Stable psychopharmacological treatment for at least one month. Exclusion Criteria: * Co-morbidity with organic diseases that could interfere with magnetic stimulation safety (epilepsy, brain lesions or diseases, previous neurosurgery, metal grafts, cardiac devices) based on applied procedure guidelines; * Diagnosis of Substance or Alcohol Use Disorder (DSM-5) in the past 6 months; * Substances of abuse or alcohol acute intoxication or abstinence; * Co-morbidity with significant organic or neurological diseases; * Personal or familiar (1st degree relatives) medical history of seizures; * Significant eye diseases that could interfere with ERG execution; * For female patients: Pregnancy/breastfeeding.

Skills for Wellness

NCT01980147
Recruiting
Conditions Schizophrenia, Bipolar Disorder, Major D...
Phase NA
Enrollment 360
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

Severe mental illness such as schizophrenia and mood disorders typically develops at a young age and can cause life-long disability. Currently available treatments cannot cure severe mental illness. This makes it important to find ways to prevent severe mental illness in young people before it has a chance to develop. This research study will pilot a new preventive intervention for young people who are at high risk of developing severe mental illness. The investigators will target early preceding factors (the 'antecedents') to severe mental illness which includes anxiety, unusual hearing and visual experiences, the loss of previously acquired abilities, and sudden and unpredictable changes in mood. These antecedents strongly predict an increased risk of developing severe mental illness. They are often impairing and distressing to the individual but can be improved with self-management skills and parent training, and they are present in the individual years before the onset of severe mental illness which makes them an ideal target for early intervention. The goal is to intervene early enough in the young person's life that severe mental illness can be prevented, hopefully leading to a happy, healthy and productive adulthood. The investigators want to test the acceptability and short-term efficacy of this new preventive intervention.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: maCBT — Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.

Primary Outcomes

  • Early antecedents to severe mental illness (4-6 months after the end of the intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2014-03-22
Completion: 2028-06-30
Eligibility
Age: 9 Years – 21 Years
Sex: ALL
Volunteers: false
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nova Scotia Health Authority
Collaborators: Nova Scotia Health Research Foundation, Canadian Institutes of Health Research (CIHR)
Principal Investigators:
  • Rudolf Uher, MD PhD (PRINCIPAL_INVESTIGATOR) - Nova Scotia Health Authority
Contact Information
Study Contact:
Rudolf Uher, MD PhD
uher@dal.ca
Nova Scotia Health Authority
Jill Cumby, RN
jill.cumby@nshealth.ca
Nova Scotia Health Authority
Interventions
  • Behavioral: maCBT — Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
Study Locations (2 sites)
Nova Scotia Health Authority, Halifax, Nova Scotia B3H 2E2 Canada
Nova Scotia Health Authority, Halifax, Nova Scotia B3H 2E2 Canada
Eligibility Criteria
Inclusion Criteria: * FORBOW (Families Overcoming Risks and Building Opportunities for Well-Being) participant between 9-21 years old * Meet criteria for one or more antecedents (psychotic like experience, basic symptoms, anxiety or affective lability) Exclusion Criteria: * Diagnosis of severe mental illness (schizophrenia, other psychotic disorder, bipolar disorder, severe major depressive disorder) * More than 3 sessions of structured psychological therapy in the past 12 months * Insufficient understanding of the English language to benefit from the intervention
Conditions Breast Cancer Female NOS, General Anxiet...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-06
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate whether psychological status affects the response to neoadjuvant immunotherapy in triple-negative breast cancer (TNBC) and how it relates to immune changes during treatment. Participants will receive standard therapy, undergo psychological assessments, and provide blood and saliva samples for biomarker testing. By linking psychological status with immune profiles and treatment outcomes, the study seeks to clarify how mental state may influence immunotherapy effectiveness.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Pathological Complete Response (pCR) Rate (At the time of definitive surgery)
  • Event-Free Survival (EFS) (18 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-01
Completion: 2027-06-30
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Zhi-Ming Shao
+86-021-64175590
zhimin_shao@yeah.net
Zhi-Ming Shao
+86-021-64175590
zhimin_shao@yeah.net
Fudan University Shangahi Cancer Center
Interventions
N/A
Study Locations (1 sites)
Fudan University Shangahi Cancer Center, Shanghai, Please Select 20080 China
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the following criteria: 1. Age ≥ 18 years; 2. Female patients; 3. Voluntarily agrees to participate in the study and signs the informed consent form, with good compliance and willingness to complete follow-up assessments; 4. Histologically confirmed invasive triple-negative breast cancer (TNBC), defined as ER \< 1%, PR \< 1%, and HER-2 0-1+ by IHC, or HER-2 2+ with negative FISH/CISH results (no gene amplification); 5. Planned to receive neoadjuvant immunotherapy-based treatment as part of routine clinical care. Exclusion Criteria Patients will be excluded if any of the following conditions apply: 1. Presence of distant metastasis; 2. History of other malignancies, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or cancers with no evidence of disease for ≥ 5 years; 3. Participation in another clinical trial and receipt of an investigational drug or treatment within 30 days before initiation of neoadjuvant therapy; 4. Known immunodeficiency or HIV infection; 5. Severe cardiac, pulmonary, hepatic, or renal dysfunction; 6. Uncontrolled infection or active systemic infection; 7. Pregnancy or breastfeeding; 8. Severe psychological or cognitive impairment that precludes completion of psychological assessments.